Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,274.05 -131.61 (-0.34%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,152.29 +8.16 (+0.10%) Bitcoin USD
57,775.28 -3,485.68 (-5.69%) CMC Crypto 200
1,236.69 -102.38 (-7.64%)
Gossamer Bio, Inc. (GOSS)
After hours:
| Previous close | 0.6963 |
| Open | 0.7350 |
| Bid | 0.7081 x 200 |
| Ask | 0.7224 x 100 |
| Day's range | 0.6542 - 0.7480 |
| 52-week range | 0.4530 - 1.8800 |
| Volume | |
| Avg. volume | 1,434,027 |
| Market cap | 160.615M |
| Beta (5Y monthly) | 1.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
SAN DIEGO, March 12, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors. Dr. Nathan is Medical Director of Inova’s Advanced Lung Disease Program and Lung Transplant
- Business Wire
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
SAN DIEGO, March 05, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.
- Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, January 08, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5, 2024, to two new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company’s com
